1-2 of 2
Evan Hersh
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Serial Monitoring of Circulating Tumor Cells Predicts Outcome of Induction Biochemotherapy plus Maintenance Biotherapy for Metastatic Melanoma

Kazuo Koyanagi, Steven J. O'Day, Peter Boasberg, Michael B. Atkins, He-Jing Wang, Rene Gonzalez, Karl Lewis, John A. Thompson, Clay M. Anderson, Jose Lutzky, Thomas T. Amatruda, Evan Hersh, Jon Richards, Jeffrey S. Weber, Dave S.B. Hoon
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (8): 2402–2408.
https://doi.org/10.1158/1078-0432.CCR-10-0037
Published: 14 April 2010
View article titled, Serial Monitoring of Circulating Tumor Cells Predicts Outcome of Induction Biochemotherapy plus Maintenance Biotherapy for Metastatic Melanoma
Open the PDF for Serial Monitoring of Circulating Tumor Cells Predicts Outcome of Induction Biochemotherapy plus Maintenance Biotherapy for Metastatic Melanoma in another window
Journal Articles

A Phase I Study of the Dolastatin-15 Analogue Tasidotin (ILX651) Administered Intravenously Daily for 5 Consecutive Days Every 3 Weeks in Patients with Advanced Solid Tumors

Scot Ebbinghaus, Eric Rubin, Evan Hersh, Lee D. Cranmer, Peter L. Bonate, Robert J. Fram, Antti Jekunen, Steve Weitman, Lisa A. Hammond
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (21): 7807–7816.
https://doi.org/10.1158/1078-0432.CCR-05-0909
Published: 08 November 2005
View article titled, A Phase I Study of the Dolastatin-15 Analogue Tasidotin (ILX651) Administered Intravenously Daily for 5 Consecutive Days Every 3 Weeks in Patients with Advanced Solid Tumors
Open the PDF for A Phase I Study of the Dolastatin-15 Analogue Tasidotin (ILX651) Administered Intravenously Daily for 5 Consecutive Days Every 3 Weeks in Patients with Advanced Solid Tumors in another window